ArticleNature microbiology2020
LY6E impairs coronavirus fusion and confers immune control of viral disease.
Open access · bronzeAbstract read
In one paragraph
Article in Nature microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
170 citing papers in PubMed, 2 syntheses or guidelines pooled it, 234 citations in OpenAlex.
- Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal HCoVs.Nature genetics · 2022Pooled it
- Dynamic data-driven meta-analysis for prioritisation of host genes implicated in COVID-19.Scientific reports · 2020Pooled it
- Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolution.Microbiology spectrum · 2026Trial
- A knockout screening platform for interferon-stimulated genes in respiratory cells identifies LY6E as a dominant antiviral effector against coronaviruses.bioRxiv : the preprint server for biology · 2026Article
- LY6E regulates Pseudorabies virus early infection via impairing viral internalization.Veterinary research · 2026Article
- Temperature-dependent replication and sensitivity to innate immunity of human coronavirus HKU1.Nature communications · 2026Article
- Alternative splicing broadens antiviral diversity at the human OAS2 locus.The EMBO journal · 2026Article
- The ISG Atlas: a loss-of-function analysis characterizes antiviral properties of interferon stimulated genes.Nature communications · 2026Article
- From CRISPR functional genomics to synthetic interventions: engineering antiviral strategies.Journal of virology · 2026Review
- Genetic and chemical correction of cystic fibrosis reduces airway susceptibility to SARS-CoV-2.American journal of physiology. Lung cellular and molecular physiology · 2026Article
- The role of peripheral serotonin in SARS-CoV-2 infectivity, COVID-19 treatment and long COVID.Immunology and cell biology · 2026Review
- Entry, replication and innate immunity evasion of BANAL-236, a SARS-CoV-2-related bat virus, in Rhinolophus and human cells.PLoS pathogens · 2026Article
- COVID-19, the disease that changed the world.Medicine and pharmacy reports · 2026Review
- TNF inhibits SARS-CoV-2 induced cell-cell fusion through activating the SDC4-RhoA signaling to promote actin bundles formation.Cell insight · 2026Article
- Inhibition of coronaviral exoribonuclease activity by TRIM-mediated SUMOylation.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- GFP-Tagged EViruses · 2026Article
- The OAS-RNase L pathway: Insights from experiments of nature.Science immunology · 2026Review
- Interferon-stimulated gene GALNT2 restricts respiratory virus infections.Nature microbiology · 2026Article
- The cost of persistent alarm: temporal transcriptional reprogramming of macrophages from acute activation to chronic immune suppression by day 11.Frontiers in immunology · 2026Article
- LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants.Cell proliferation · 2025Article
110 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
27 authors at 8 institutions in 3 countries.
Stephanie Pfaender *Institute of Virology and Immunology, Bern, Switzerland.ORCID http://orcid.org/0000-0002-3957-5448
Katrina B Mar *Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0003-3640-2418
Eleftherios MichailidisLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-9907-4346
Annika KratzelInstitute of Virology and Immunology, Bern, Switzerland.ORCID http://orcid.org/0000-0001-8468-4742
Ian N BoysDepartment of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0002-0854-207X
Philip V'kovskiInstitute of Virology and Immunology, Bern, Switzerland.ORCID http://orcid.org/0000-0002-8366-1220
Wenchun FanDepartment of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0002-0554-1362
Jenna N KellyInstitute of Virology and Immunology, Bern, Switzerland.ORCID http://orcid.org/0000-0001-7265-2233
Dagny HirtInstitute of Virology and Immunology, Bern, Switzerland.
Nadine EbertInstitute of Virology and Immunology, Bern, Switzerland.
Hanspeter StalderInstitute of Virology and Immunology, Bern, Switzerland.ORCID http://orcid.org/0000-0003-0763-6469
Hannah Kleine-WeberDeutsches Primatenzentrum, Leibniz-Institut für Primatenforschung, Göttingen, Germany.
Markus HoffmannDeutsches Primatenzentrum, Leibniz-Institut für Primatenforschung, Göttingen, Germany.ORCID http://orcid.org/0000-0003-4603-7696
Hans-Heinrich HoffmannLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-0554-0244
Mohsan SaeedLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Ronald DijkmanInstitute of Virology and Immunology, Bern, Switzerland.ORCID http://orcid.org/0000-0003-0320-2743
Eike SteinmannDepartment for Molecular and Medical Virology, Ruhr-Universität Bochum, Bochum, Germany.
Mary Wight-CarterAnimal Resource Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Matthew B McDougalDepartment of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0002-3957-8868
Natasha W HannersDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0002-3391-4197
Stefan PöhlmannDeutsches Primatenzentrum, Leibniz-Institut für Primatenforschung, Göttingen, Germany.ORCID http://orcid.org/0000-0001-6086-9136
Tom GallagherDepartment of Microbiology and Immunology, Loyola University Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-8601-5961
Daniel TodtDepartment for Molecular and Medical Virology, Ruhr-Universität Bochum, Bochum, Germany.ORCID http://orcid.org/0000-0002-3564-1014
Gert ZimmerInstitute of Virology and Immunology, Bern, Switzerland.ORCID http://orcid.org/0000-0002-2708-2507
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA. ricec@rockefeller.edu.ORCID http://orcid.org/0000-0003-3087-8079
John W SchogginsDepartment of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. john.schoggins@utsouthwestern.edu.ORCID http://orcid.org/0000-0002-7944-6800
Volker ThielInstitute of Virology and Immunology, Bern, Switzerland. volker.thiel@vetsuisse.unibe.ch.ORCID http://orcid.org/0000-0002-5783-0887
University of Bern · CHThe University of Texas Southwestern Medical Center · USGerman Primate Center · DERockefeller University · USRuhr University Bochum · DEBoston University · USLoyola University Chicago · USSouthwestern Medical Center · US
Funding
SARS-CoV Proteins in Heterologous Viral InfectionP01AI060699 · NIAID · UNIVERSITY OF IOWA · PI PERLMAN, STANLEY · 2004 to 2021
$21.5MINTEGRATIVE IMMUNOLOGY TRAINING PROGRAMT32AI005284 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Nan Yan · 2003 to 2026
$7.4MType I interferon-stimulated genes and the antiviral immune responseR01AI091707 · NIAID · ROCKEFELLER UNIVERSITY · PI RICE, CHARLES M · 2011 to 2020
$5.5MDiscovery of antiviral mechanisms in batsDP2AI117922 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI SCHOGGINS, JOHN W. · 2014 to 2016
$2.6MInterferon-mediated control of neuropathogenic FlavivirusesK08AI132751 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI HANNERS, NATASHA WYNDHAM · 2019 to 2023
$744kBundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 01KI1723ABundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 01KI1723DBurroughs Wellcome Fund (BWF) 'Investigators in the Pathogenesis of Infectious Diseases' AwardNational Science Foundation (NSF) 2016217834National Science Foundation (NSF) 2019274212NIAID NIH HHS DP2 AI117922NIAID NIH HHS K08 AI132751NIAID NIH HHS P01 AI060699NIAID NIH HHS R01 AI091707NIAID NIH HHS T32 AI005284Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 166265Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 173085Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 179260Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 310030Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 310030_173085Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) CRSII3_160780U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI005284U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI091707U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI091707-10S1U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI117922U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI132751
Abstract
Zoonotic coronaviruses (CoVs) are substantial threats to global health, as exemplified by the emergence of two severe acute respiratory syndrome CoVs (SARS-CoV and SARS-CoV-2) and Middle East respiratory syndrome CoV (MERS-CoV) within two decades
Indexed as
Angiotensin-Converting Enzyme 2AnimalsAntigens, SurfaceBetacoronavirusCoronavirusCoronavirus InfectionsCOVID-19FemaleGPI-Linked ProteinsMaleMiceMice, Inbred C57BLMice, KnockoutMiddle East Respiratory Syndrome CoronavirusPandemicsPeptidyl-Dipeptidase AACE2 protein, humanAce2 protein, mouseAngiotensin-Converting Enzyme 2Antigens, SurfaceGPI-Linked ProteinsLy6e protein, mousePeptidyl-Dipeptidase A
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.